China Grants World-First Commercial License for Implantable BCI Restoring Hand Function

States have jockeyed for neuro-device firsts since the cardiac pacemaker (first implant 1958, Sweden) and the FDA’s cochlear-implant approval in 1984; China now seizes a similar milestone in the brain domain, leap-frogging the U.S., where Neuralink and BrainGate remain in trials. The move reflects long-term trends: Beijing’s five-year plans increasingly target frontier bio-hardware, and its regulators—unencumbered by U.S. tort law and fragmented ethics boards—can move from lab to market in half the Western time, much as Japan’s MITI accelerated semiconductor production in the 1970s. If safe and scalable, invasive BCIs could shift rehabilitation and even human-machine symbiosis over the next century, but the same tools invite surveillance, cognitive-data extraction, and techno-nationalist arms races. Whether 2026 is remembered like 1947’s first transistor or like 1978’s Concorde (a technical marvel with limited uptake) will depend on post-market outcomes and global norms on neural data privacy.